Biologists working with engineers and physicists have found a molecule they say helps determine if breast cancer cells that are resistant to antiestrogen therapy will live or die.
Their study, published online earlier this month in Cancer Research, represents a major finding from a unique collaboration between Georgetown Lombardi Comprehensive Cancer Center and Virginia Tech that was designed to study the living cell as an information processing system.
"We needed an engineering approach to a biological problem—no one had built a model like this before," said the project's principal investigator, Robert Clarke, PhD, DSc., Dean for Research at Georgetown University Medical Center.
His team consists of oncology and genetic researchers from Georgetown Lombardi and electrical and computer engineers, and bioinformatics specialists from Virginia Tech.
The scientists created a mathematical model that uses all of the biological data known to date about estrogen-positive breast cancer to understand the decisions that tumor cells make to ensure their survival, based on signals from their environment and their own internal state. It is supported by a $7.5 million federal grant.
"A cell is vastly harder to model than engineered systems, such as the nation's electrical grid or a complex integrated circuit, because of the incredible number of interactions among its components," explains Virginia Tech electrical engineer William T. Baumann, PhD, associate professor in the Bradley Department of Electrical and Computer Engineering, and co-author of the paper. "We are just at the beginning of being able to model an entire cell."
This approach may be key to understanding why many of the approximately 125,000 patients diagnosed with estrogen-positive breast cancer (meaning their cancer growth is fueled by the hormone) become resistant to antiestrogen therapy—such as tamoxifen, fulvestrant and aromatase inhibitors.
The problem has not been solved in the 30 years since some of these treatments have been used, Clarke says. "The result is that many estrogen-positive tumors recur as incurable, endocrine-resistant cancer cells," he adds.
Using their model, the team found a key molecular component that determines whether a breast cancer cell will turn on autophagy—a process wherein a cell chews up and eliminates toxic proteins to stay alive—or switch on apoptosis, which pushes the cell to die. This molecule, interferon regulatory factor-1 (IRF1), is engaged when a cell is under stress, such as by antiestrogen treatment.
Loss of IRF1 promoted resistance to antiestrogens, whereas silencing of IRF1 restored sensitivity to the agents, Clarke says.
Clarke says modeling "helps you find things that may be quite important that you would not have discovered using intuition alone. The molecular logic of these circuits is difficult to comprehend by intuitive reasoning, and I know had we not had the model, we would have stopped our experiments before we discovered the importance of the IRF1 signal."
Explore further: Tamoxifen-resistant breast cancer reversed when drug paired with anti-malaria agent
Medical Xpress on facebook
Related Stories
Tamoxifen-resistant breast cancer reversed when drug paired with anti-malaria agent
Jun 13, 2014
The inexpensive anti-malarial drug hydroxychloroquine (HCQ) reverses resistance to tamoxifen, a widely used breast cancer drug, in mice.
Roadmap published for dynamic mapping of estrogen signaling in breast cancer
Jun 16, 2011
The first roadmap to mathematical modeling of a powerful basic "decision circuit" in breast cancer has been developed and published in Nature Reviews Cancer.
Researchers discover new way to 'rescue' treatment sensitivity of breast cancer cells
May 10, 2010
A study by researchers from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC) identifies a potential new combination therapy to "rescue" treatment sensitivity to fulvestrant ...
Scientists link gene to tamoxifen-resistant breast cancers
Nov 25, 2014
After mining the genetic records of thousands of breast cancer patients, researchers from the Johns Hopkins Kimmel Cancer Center have identified a gene whose presence may explain why some breast cancers are ...
Excess estrogen in pregnancy can silence BRCA1 in daughters, increasing breast cancer risk
Apr 09, 2013
Excess estrogen levels during pregnancy can disable, in their daughters, a powerful breast cancer tumor suppressor gene, say researchers at Georgetown Lombardi Comprehensive Cancer Center. They found the DNA repair gene BRCA1 ...
Recommended for you
Swedish model for PSA testing has little effect on mortality
26 minutes ago
The spontaneous PSA testing that has been applied in Sweden in recent decades has only had a marginal effect on mortality. An organized screening focused on those who have the most to gain would, however, reduce the risk ...
How cancer turns good cells to the dark side
54 minutes ago
Cancer uses a little-understood element of cell signaling to hijack the communication process and spread, according to Rice University researchers.
New exam nearly quadruples detection of invasive breast cancers in dense breast tissue
3 hours ago
A new breast imaging technique pioneered at Mayo Clinic nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a major study published this week in the ...
Many women with breast cancer have poor knowledge about their condition
10 hours ago
A new analysis has found that many women with breast cancer lack knowledge about their illness, with minority patients less likely than white patients to know and report accurate information about their tumors' characteristics. ...
Patients dismissing 'trivial' symptoms could delay cancer diagnosis
15 hours ago
People who dismiss their symptoms as trivial or worry about wasting the doctor's time may decide against going to their GP with red-flag cancer warning symptoms, according to a Cancer Research UK study* published in the British Jo ...
Loss of loved ones drives a family's determination to eradicate cancer
Jan 24, 2015
Alison Brown-Carvalho lost her husband William Brown to pancreatic cancer in 2009, after 16 years of marriage. A few years later she lost her mother, Janet (Ikeda) Shitabata, to stomach cancer.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
Biologists working with engineers and physicists have found a molecule they say helps determine if breast cancer cells that are resistant to antiestrogen therapy will live or die.
Their study, published online earlier this month in Cancer Research, represents a major finding from a unique collaboration between Georgetown Lombardi Comprehensive Cancer Center and Virginia Tech that was designed to study the living cell as an information processing system.
"We needed an engineering approach to a biological problem—no one had built a model like this before," said the project's principal investigator, Robert Clarke, PhD, DSc., Dean for Research at Georgetown University Medical Center.
His team consists of oncology and genetic researchers from Georgetown Lombardi and electrical and computer engineers, and bioinformatics specialists from Virginia Tech.
The scientists created a mathematical model that uses all of the biological data known to date about estrogen-positive breast cancer to understand the decisions that tumor cells make to ensure their survival, based on signals from their environment and their own internal state. It is supported by a $7.5 million federal grant.
"A cell is vastly harder to model than engineered systems, such as the nation's electrical grid or a complex integrated circuit, because of the incredible number of interactions among its components," explains Virginia Tech electrical engineer William T. Baumann, PhD, associate professor in the Bradley Department of Electrical and Computer Engineering, and co-author of the paper. "We are just at the beginning of being able to model an entire cell."
This approach may be key to understanding why many of the approximately 125,000 patients diagnosed with estrogen-positive breast cancer (meaning their cancer growth is fueled by the hormone) become resistant to antiestrogen therapy—such as tamoxifen, fulvestrant and aromatase inhibitors.
The problem has not been solved in the 30 years since some of these treatments have been used, Clarke says. "The result is that many estrogen-positive tumors recur as incurable, endocrine-resistant cancer cells," he adds.
Using their model, the team found a key molecular component that determines whether a breast cancer cell will turn on autophagy—a process wherein a cell chews up and eliminates toxic proteins to stay alive—or switch on apoptosis, which pushes the cell to die. This molecule, interferon regulatory factor-1 (IRF1), is engaged when a cell is under stress, such as by antiestrogen treatment.
Loss of IRF1 promoted resistance to antiestrogens, whereas silencing of IRF1 restored sensitivity to the agents, Clarke says.
Clarke says modeling "helps you find things that may be quite important that you would not have discovered using intuition alone. The molecular logic of these circuits is difficult to comprehend by intuitive reasoning, and I know had we not had the model, we would have stopped our experiments before we discovered the importance of the IRF1 signal."
Explore further: Tamoxifen-resistant breast cancer reversed when drug paired with anti-malaria agent
Medical Xpress on facebook
Related Stories
Tamoxifen-resistant breast cancer reversed when drug paired with anti-malaria agent
Jun 13, 2014
The inexpensive anti-malarial drug hydroxychloroquine (HCQ) reverses resistance to tamoxifen, a widely used breast cancer drug, in mice.
Roadmap published for dynamic mapping of estrogen signaling in breast cancer
Jun 16, 2011
The first roadmap to mathematical modeling of a powerful basic "decision circuit" in breast cancer has been developed and published in Nature Reviews Cancer.
Researchers discover new way to 'rescue' treatment sensitivity of breast cancer cells
May 10, 2010
A study by researchers from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC) identifies a potential new combination therapy to "rescue" treatment sensitivity to fulvestrant ...
Scientists link gene to tamoxifen-resistant breast cancers
Nov 25, 2014
After mining the genetic records of thousands of breast cancer patients, researchers from the Johns Hopkins Kimmel Cancer Center have identified a gene whose presence may explain why some breast cancers are ...
Excess estrogen in pregnancy can silence BRCA1 in daughters, increasing breast cancer risk
Apr 09, 2013
Excess estrogen levels during pregnancy can disable, in their daughters, a powerful breast cancer tumor suppressor gene, say researchers at Georgetown Lombardi Comprehensive Cancer Center. They found the DNA repair gene BRCA1 ...
Recommended for you
Swedish model for PSA testing has little effect on mortality
26 minutes ago
The spontaneous PSA testing that has been applied in Sweden in recent decades has only had a marginal effect on mortality. An organized screening focused on those who have the most to gain would, however, reduce the risk ...
How cancer turns good cells to the dark side
54 minutes ago
Cancer uses a little-understood element of cell signaling to hijack the communication process and spread, according to Rice University researchers.
New exam nearly quadruples detection of invasive breast cancers in dense breast tissue
3 hours ago
A new breast imaging technique pioneered at Mayo Clinic nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a major study published this week in the ...
Many women with breast cancer have poor knowledge about their condition
10 hours ago
A new analysis has found that many women with breast cancer lack knowledge about their illness, with minority patients less likely than white patients to know and report accurate information about their tumors' characteristics. ...
Patients dismissing 'trivial' symptoms could delay cancer diagnosis
15 hours ago
People who dismiss their symptoms as trivial or worry about wasting the doctor's time may decide against going to their GP with red-flag cancer warning symptoms, according to a Cancer Research UK study* published in the British Jo ...
Loss of loved ones drives a family's determination to eradicate cancer
Jan 24, 2015
Alison Brown-Carvalho lost her husband William Brown to pancreatic cancer in 2009, after 16 years of marriage. A few years later she lost her mother, Janet (Ikeda) Shitabata, to stomach cancer.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment